Objective: Fish oil (FO) may attenuate the inflammatory response after major surgery such as abdominal aortic aneurysm (AAA) surgery. We aimed at evaluating the clinical impact and safety aspects of a FO containing parenteral nutrition (PN) after AAA surgery. Methods: Intervention consisted in 4 days of either standard (STD: Lipofundin medium-chain triglyceride (MCT): long-chain triglyceride (LCT)50%-MCT50%) or FO containing PN (FO: Lipoplus: LCT40%-MCT50%-FO10%). Energy target were set at 1.3 times the preoperative resting energy expenditure by indirect calorimetry. Blood sampling on days 0, 2, 3 and 4. Glucose turnover by the 2 H 2 -glucose method. Muscle microdialysis. Clinical data: maximal daily T1, intensive care unit (ICU) and hospital stay. Results: Both solutions were clinically well tolerated, without any differences in laboratory safety parameters, inflammatory, metabolic data, or in organ failures. Plasma tocopherol increased similarly; with FO, docosahexaenoic and eicosapentaenoic acid increased significantly by day 4 versus baseline or STD. To increased postoperatively, with a trend to lower values in FO group (P ¼ 0.09). After FO, a trend toward shorter ICU stay (1.670.4 versus 2.370.4), and hospital stay (9.972.4 versus 11.372.7 days: P ¼ 0.19) was observed. Conclusions: Both lipid emulsions were well tolerated. FO-PN enhanced the plasma n-3 polyunsaturated fatty acid content, and was associated with trends to lower body temperature and shorter length of stay.
Introduction
Among surgical procedures, the standardized aortic crossclamping required for abdominal aortic aneurysm (AAA) surgery, is a stereotyped clinical model of acute ischaemia reperfusion, which causes an intense inflammatory response. Such major surgery induces extensive physiological responses, including insulin resistance, activation of white blood cells and endothelium, and release of pro-inflammatory mediators.
Two families of polyunsaturated fatty acids (PUFAs) are particularly important for human health, the nÀ3 and the nÀ6: the former are contained in fish oil (FO: nÀ3 long-chain (LC) PUFA) and the 18 carbon precursor a-linolenic acid in some vegetable oils; the nÀ6 PUFAs are contained in animal (nÀ6 LC-PUFA) and the 18 carbon precursor linoleic acid in vegetable oils (Calder, 2004) . The nÀ3 PUFAs family has many compounds, including a-linolenic, eicosapentaenoic (EPA: C20:5 nÀ3) and docosahexaenoic (DHA: C22:6 nÀ3) acids. After incorporation into cell membranes, they influence the expression of numerous genes, membrane fluidity, opening of ion channels, recognition and function of membrane receptors, eicosanoid synthesis, second messenger synthesis, as well as many signalling and metabolic pathways. This will affect many important cell functions (Calder and Deckelbaum, 1999; Finnegan et al., 2003) , including modulation of inflammatory responses by inhibition of pro-inflammatory cytokine production and the stress response (Calder, 2004) . The development of FO solutions for parenteral nutrition (PN) enables short intravenous interventions provided over a few hours or days to exert targeted effects in patients (Krohn and Koletzko, 2006) . Among the non-energetic effects of lipids that are potentially useful in critically ill patients (Calder and Deckelbaum, 1999; Fürst, 2000) , the modulation of carbohydrate metabolism and of the inflammatory response are the most important. In vitro data suggest that nÀ3 PUFAs inhibit the de novo lipogenesis, a biochemical process during which carbohydrates are transformed into fatty acids (Klein et al., 1997) . Experimental and clinical data suggest that this type of regulation might be favourable in acutely ill patients. This contrasts with a possible decrease in insulin sensitivity in patients with type II diabetes, in whom studies suggest that nÀ3 PUFAs may decrease insulin sensitivity (Puhakainen et al., 1995; Mostad et al., 2006) , a potentially undesirable effect in intensive care unit (ICU) patients. Results from our group show that such effect does not seem to be significant in the critically ill (Tappy et al., 2006) .
We hypothesized that early postoperative intravenous FO supplementation may modulate the physiologic postoperative responses to AAA surgery, particularly glucose kinetics, and glucose utilization in skeletal muscle. It was an additional aim to evaluate the effects of FO on plasma lactic acid concentrations and skeletal muscle lacticogenesis in critically ill patients. Since several experimental works supported the hypothesis that increased lactate production may be related to a stimulation of Na-K ATPase in sepsis (McCarter et al., 2002; Bundgaard et al., 2003; Hsieh et al., 2003) , we attempted to specifically assess the effects of FO on Na-K ATPase-dependent lactic acid formation. The study finally aimed at testing the safety and the clinical impact of FO containing PN after this type of surgery.
Methods
The study was designed as a prospective, randomized, double-blind placebo-controlled trial in adult patients requiring intensive care after AAA surgery and requiring PN. It was approved by the Institutional Ethics Committee, and was conducted in the surgical unit of the Intensive Care Medicine Department of CHUV in Lausanne.
Exclusion criteria: These were absence of consent, insulin requiring diabetes mellitus, morbid obesity (body mass index (BMI)435), corticosteroid treatment, active haemorrhage or haemorrhagic shock, cardiovascular failure, hepatic or renal failure, blood clotting abnormalities (total protein o50%, activated partial thromboplastin time 440 s), platelets o60 000/mm 3 , less than 2 days of PN.
Clinical outcome data: These were daily maximum temperature (T, 1C), occurrence of renal failure (plasma creatinine increase 490 mmol/l), length of ICU and of hospital stays, and wound healing problems.
Resting energy expenditure: REE was determined preoperatively, on day 1 and on the day of metabolic investigation using a canopy and a Deltatrac Monitor (Datex Instruments, Helsinki, Finland). Initial energy target was set at 100% the preoperative REE, and increased to 130% after 18-24 h.
Intervention: The patients were randomized to receive either a medium-chain triglyceride/long-chain triglyceride (MCT/LCT) lipid emulsion (our unit's standard practice ¼ standard (STD), Lipofundin MCT: LCT 50%, MCT 50%) or a FO containing emulsion (Lipoplus: LCT 40%, MCT 50%, FO 10%; B. Braun, Melsungen, Germany) for a daily supply of 0.15 g/kg fat per day. The Lipoplus emulsion contains 20 g/ l nÀ3 LC-PUFAs including 10.45 g/l EPA and DHA. Energy partition in PN was 40% as lipids, 15% as proteins (1,2 g/kg/ day amino acids, as Modulamin, B. Braun) and 45% of energy as carbohydrates (glucose 50%). The PN was started within 2-4 h of admission to the ICU.
Measurements: The design of the metabolic investigations carried out between days 3 and 4 is summarized in Figure 1 .
Glucose turnover: A primed (2 mg/kg) continuous (2% of total carbohydrate dose) infusion of 6,6 2 H 2 -glucose (Hetenyi et al., 1982; Tappy et al., 1992) . Na-bicarbonate 1.4%, was run at a rate of 45 ml/h after a bolus 10 ml. Breath and blood samples were collected on initiation of PN, and then on the day of stable isotope metabolic investigations at times 210, 240 and 270 min to determine plasma 13 C glucose and breath 13 CO 2 enrichment. Microdialysis: A microdialysis catheter (CMA 60; CMA/ Microdialysis, Stockholm, Sweden; dialysing membrane length 30 mm, cutoff 30 000 Da) was inserted into the vastus externus muscle under local anaesthesia and was infused with either GUL solution (GUL ¼ 13 C glucose 5 mmol/l, 13 C urea 5 mmol/l, 2 H 5 lactate 1 mmol/l), or a ouabain solution (0.2 mM in 5 ml). Both infusions were prepared using either 1.8 ml GUL þ 0.2 ml NaCl 0.9%, or 1.8 ml GUL þ 0.2 ml ouabain.
13 C lactate was determined in the collected dialysate as an index of tissue lactate production Blood determinations: Glucose, insulin, glucagon, ketonic bodies, albumin, prealbumin, procalcitonin, liver function tests (asparagines aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase, gamma-GT), creatinine, C-reactive protein (CRP), clotting time, lipid profile, EPA, DHA, a-tocopherol, trolox equivalent antioxidative capacity.
Analysis

Plasma 6,6
2 H 2 glucose enrichment was measured by gas chromatography-mass spectrometry as described previously (Tappy et al., 1997) . For this analysis, plasma glucose was derivatized to pentacetyl glucose and spectrometric analysis was performed after chemical ionization, with selective monitoring of m/z 333 and 331. Plasma 13 C-lactate concentrations were measured by gas chromatography-mass spectrometry (Henry et al., 1996) . For this analysis, microdialysate lactate was derivatized to lactate-N-propylamide-heptafluorobutyrate and analysed after chemical ionization with selective monitoring of m/z 241 and 244. Microdialysate glucose and lactate concentrations were measured on a CMA 600 microdialysis analyzer (Carnegie Medicine Stockholm, Sweden).
Non-esterified fatty acid concentrations were quantified by a colorimetric method using a kit from Wako (Freiburg, Germany). The composition of fatty acids in plasma phospholipids was quantified by gas-liquid chromatography as described previously (Geppert et al., 2005) . Plasma atocopherol was measured by high-performance liquid chromatography as described previously (Geppert et al., 2006) . Malondialydehyde (MDA) was analysed after reaction with 2-thiobarbituric acid as thiobarbituric acid reactive substances (Knight et al., 1988) . The measurement of trolox equivalent antioxidative capacity is based on the inhibition of radical formation by plasma antioxidants.
Calculations
Net rates of substrate oxidation were calculated with the equations of Livesey and Elia (1988) . Whole body glucose turnover was calculated with Steele's equation for steadystate conditions (DeBodo et al., 1963) :
where: R a is the rate of appearance, R d is the rate of disappearance, F the infusion rate of labelled glucose; C the glucose concentration and IE the isotopic enrichment. A pool fraction (p) of 0.75 and a distribution volume for glucose (V d ) of 0.2 l per kg body weight were used for these calculations. Under such conditions, glucose production is equal to glucose utilization. Non-oxidative glucose utilization was calculated as (glucose production) (net glucose utilization). Rates of glucose appearance and disappearance were calculated from plasma 6,6 2 H 2 glucose enrichments. Nonoxidative glucose utilization was calculated as the difference of R d(glucose) and the net oxidation of carbohydrates calculated from indirect calorimetry.
GNG was calculated according to Hetenyi et al. (1982) as GNG ¼ ( 13 C plasma glucose IE Â 6)/breath 13 CO 2 IE Â glucose rate of appearance. Owing to loss of 13 C to CO 2 at the level of Krebs cycle intermediate, this method is known to yield systematically underestimated values, which however does not preclude between groups comparisons. For microdialysis measurements, tissue substrate production is reflected by a positive gradient of concentration between the dialysate and the systemic circulation (Binnert and Tappy, 2002) . This gradient was calculated as (dialysate concentrations)À(systemic plasma concentrations), assuming a near complete substrate recovery at the low flow rate (0 Á 3 ml/min) used in these experiments.
Statistics: Data presented as means 7s.d., medians and ranges. Baseline values were analysed using one-way analysis of variance (ANOVA) and repeated determinations with two-way ANOVA (Dunett for post hoc tests). Length of ventilation and stay were analysed using Kaplan-Meyer method. Wilcoxon test was used for non-parametric data. P-values o0.05 were considered significant, while values between 0.05 and 0.20 were considered trends. Statistical package was JMP Version 5.5., SAS Institute Inc. Cary, NC, USA. 
Results
Altogether 24 patients out of 35 eligible patients admitted to the surgical ICU completed the trial (Table 1) : 11 patients dropped out due to: surgeon's decision to delay surgery (no PN administered, n ¼ 1 in STD), PN bags not being transferred to the intermediate care resulting in less than 2 days of PN (n ¼ 4), acute renal failure requiring renal replacement therapy (n ¼ 1 in STD), patients secondary denial of consent (n ¼ 3 in FO) or introduction of corticosteroids for septic shock (n ¼ 2 in STD with one death). Age, sex distribution, BMI and Scale of Assessment of Positive Symptoms II scores did not differ between groups. All the patients received the same quantities of glucose and proteins per kg body weight. Of the 24 patients who completed the PN, four patients could not undergo microdialysis investigations (consent limited to the isotope study). There was 1 case/24 patients of postoperative renal failure. All patients were discharged alive from the hospital. Clinical data: T1 increased significantly postoperatively in both groups, with a trend to lower values in the FO group (P ¼ 0.09) (Figure 2 ). There were nonsignificant trends to shorter stays in the ICU (P ¼ 0.22) and in the hospital (P ¼ 0.19) in the FO group (Table 1) .
REE did not differ at baseline between FO 690871103 kJ (16537264 kcal) and STD 687071087 kJ (16447260 kcal). It increased modestly but significantly (P ¼ 0.0007) in both groups on day 3-4, to 737671041 kJ (17657249 kcal) and 762271279 kJ (18247306 kcal), respectively.
Safety: Both PN solutions were clinically well tolerated. There were no differences in the evolution of laboratory safety parameters, nor metabolic data.
Laboratory (Table 2) : Albumin, procalcitonin, ASAT, ALAT, alkaline phosphatase and gamma-GT did not differ. CRP increased after surgery (P ¼ 0.001; ns between groups), then normalized progressively in both groups after day 4. Prealbumin values increased more in the FO group (P ¼ 0.0049). Plasma concentrations of DHA and EPA were unchanged in the STD group but increased significantly by day 4 in the FO group compared to baseline (Po0.001). Total plasma fatty acids and arachidonic acid did not differ. Plasma MDA remained stable, and paralleled the arachidonic acid values (correlation: r 2 ¼ 0.168, Po0.001) without significant differences between groups. a-Tocopherol equivalent antioxidative capacity increased similarly in both groups over time, while trolox change was not significant.
Glucose metabolism
Morning blood glucose values tended to be lower in the FO group (P ¼ 0.18), while insulin requirements were similar. In all patients, exogenous glucose infusion with PN failed to suppress endogenous glucose production and GNG, resulting in high rates of total glucose production and utilization (Table 3 ). There was however no effect of FO on any of the studied parameters of glucose metabolism.
Microdialysis. Muscle interstitial glucose concentration was similar in both groups, and tended to decrease slightly during local ouabain infusion. Interstitial lactate and 13 C lactate synthesized from locally infused 13 C glucose were also similar in both groups, and were slightly increased during Figure 2 Evolution of temperature after surgery.
Fish oil PN after major surgery MM Berger et al ouabain infusion, to decrease again to baseline values after ouabain was stopped. Muscle interstitial glycerol was the same in both groups, and was also increased after ouabain (which may reflect tissue lesion).
Discussion and conclusion
In the present randomized controlled study, we investigated FO-supplemented PN after AAA surgery, a model of ischaemia reperfusion. The tested hypothesis was that nÀ3 PUFA would be well tolerated and might downregulate the postoperative physiological responses. Another question concerned the impact of FO on glucose metabolism.
Both standard and FO lipid emulsions were well tolerated: we observed no metabolic or biochemical alterations, nor deleterious effect on the clinical course. The FO emulsion enhanced the plasma nÀ3 LC-PUFA content, modified the triglyceride profile, and caused a significant and expected increase of plasma DHA and EPA. There was a progressive rise of triglyceride plasma levels in both groups: the most likely explanation is a relatively high fat load, amounting to 40% of total energy. This might be beneficial considering the existing data on systemic inflammatory response syndrome. Since low cholesterol has been shown to be associated with increased mortality in critically ill patients (Bonville et al., 2004) , and as high high-density lipoprotein cholesterol binds cholesterol (Levine et al., 1993) , serum lipid repletion may become a therapeutic approach for the management of critical illness. The clinical course was uneventful tending to be smoother in the FO group, as reflected by the trends to lower body temperature and shorter length.
Metabolic effects
The metabolic investigations showed no significant effect on REE after 4 days of PN. This contrasts with another recent clinical investigation by our group in 24 septic and Plasma glucose, glucose turnover, oxidation and production, GNG, hepatic de novo lipogenesis, insulin and glucagon concentrations were not influenced by the fat solution, in agreement with our previous study in septic patients (Tappy et al., 2006) . The failure of PN to shutdown glucose production, like in healthy subjects, has been widely documented in critically ill patient, and is a hallmark of the metabolic response to stress (Tappy et al., 1998) . This contrasts with type II diabetic patients in whom decreased insulin sensitivity and time-dependent alterations from carbohydrate to fat oxidation have been observed during FO supplementation (Mostad et al., 2006) . Although we are confident in our two consecutive trials showing limited effects of FO in critically ill patients, we consider that further investigations are required, since glucose control is a major objective in ICU patients.
There were no systemic effects on lactate metabolism: plasma lactate concentrations did not differ between groups. Muscle microdialysis with local ouabain infusion was used to investigate if FO would modulate lactate concentration in the skeletal muscle, a surrogate of the Na-K ATPase muscle activity: for this purpose, we infused ouabain in the microdialysis catheter to inhibit the enzyme. As the Na-K ATPase activity is considered to be increased during inflammation, contributing to hyperlactatemia (Levy et al., 2005) , our observation of an increased lactate muscle release during Na-K ATPase inhibition by ouabain appears surprising. Given the concomitant increase in glycerol, we however suspect that these alterations may merely reflect a moderate local toxic effect of high concentrations of ouabain on skeletal muscle. Altogether our data suggest that FO does not significantly contribute to hyperlactatemia after AAA.
Clinical effects
We observed no significant clinical effects related to FO administration, except for minor effects on body temperature and length of stay. This contrasts with beneficial effects reported in uncontrolled trials in critically ill patients receiving FO-enriched PN.
In 661 critically ill patients receiving various doses of FO, Heller et al. observed favourable effects on survival, infection rates and length of stay. The most positive effects were observed in doses between 0.1 and 0.2 g/kg/day. In another retrospective study, (Tsekos et al. (2004) analysed a 2-yearlongitudinal database including 249 ICU patients receiving PN after major abdominal surgery: they found a lower mortality in patients receiving FO-supplemented PN compared with conventional fat. The most likely explanation for this discrepancy is related to the limited power of our study and to the patient characteristics (elective moderate stress surgery, low complication rate and no mortality). Another explanation could be related to the small composition differences in the two lipid solutions, which was indeed limited to the exchange of 25% of the total LCT content by FO, both solutions including 50% of MCT. This may by too small a difference to achieve major clinical effects. The high fat load in our study may also have blunted the favourable effects of FO. Indeed, present recommendations in critical illness propose to limit fat intake to about 20-35% of total energy intake.
Altogether, these data show that the FO containing lipid emulsion is safe and well tolerated, without any impact on glucose metabolism in critically ill surgical patients. FO-PN may even have beneficial clinical effects, considering the lower peak temperature, and the trends to shorter hospital stay.
